A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Michael A Weber, Traci A Mansfield, Valerie A Cain, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Lancet Diabetes Endocrinol 2016
Times Cited: 120




List of shared articles



Times cited

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, Maria I Markou, Erifili E Hatziagelaki, Charalampos A Grassos, Maria L Velliou, John D Barbetseas. Am J Cardiovasc Drugs 2021
0

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
0

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Elias A Sanidas, Dimitrios P Papadopoulos, Erifili Hatziagelaki, Charalampos Grassos, Maria Velliou, John Barbetseas. Am J Hypertens 2020
5


Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3

SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution.
Karen C Tran, Swapnil Hiremath. Am J Hypertens 2020
0


Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Aris Liakos, Vaia Lambadiari, Alexandra Bargiota, Konstantinos Kitsios, Iakovos Avramidis, Kalliopi Kotsa, Spyridon Gerou, Panagiota Boura, Nikolaos Tentolouris, George Dimitriadis,[...]. Diabetes Obes Metab 2019
10

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019
19

Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy.
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho, Andrei C Sposito. Rev Assoc Med Bras (1992) 2019
9

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Keith C Ferdinand, Joseph L Izzo, Jisoo Lee, Leslie Meng, Jyothis George, Afshin Salsali, Leo Seman. Circulation 2019
27

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
53



Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Surender Kumar, Pradeep G Talwalkar, Sambit Das, Soumik Goswami. Indian J Endocrinol Metab 2019
1

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
11



Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2019
17